Hepatitis C Virus Nucleocapsid Recombinant Protein | HCV recombinant protein

Recombinant Hepatitis C Virus Nucleocapsid (core) Genotype-4

Cat. Num. AAA142532

• Applications: ELISA, Western Blot
• Purity: Purity: Protein is >95% pure as determined by 10% PAGE (coomassie staining).; Purification Method: Purified by proprietary chromatographic technique.
• Synonyms: Hepatitis C Virus Nucleocapsid; Recombinant Hepatitis C Virus Nucleocapsid (core) Genotype-4; HCV Core Genotype-4; Hepatitis C Virus Core Genotype-4 Recombinant; HCV Genotype-4; HCV recombinant protein

• Specificity: Immunoreactive with sera of HCV-infected individuals.
• Purity/Purification: Purity: Protein is >95% pure as determined by 10% PAGE (coomassie staining).; Purification Method: Purified by proprietary chromatographic technique.
• Form/Format: (1mg/ml) 50mM Tris-HCl, pH 8.0, 60mM NaCl, 10mM glutathione, 0.25% sarkosil and 50% glycerol.
• Concentration: 1mg/ml (varies by lot)
• Sequence Length: 3008

• Applicable Applications for HCV recombinant protein: ELISA (EIA), Western Blot (WB)
• Application Notes: Antigen in ELISA and Western blots, excellent antigen for detection of HCV with minimal specificity problems.
• Preparation and Storage: HCV Core Genotype-4 although stable at 4°C for 1 week, should be stored below -18°C. Please prevent freeze thaw cycles.

Related Product Information for HCV recombinant protein

Description: The E Coli derived recombinant protein contains the HCV core nucleocapsid immunodominant regions, amino acids 2-119. The protein is fused to a GST tag at N-Terminus.

Introduction: HCV is a small 50nm, enveloped, single-stranded, positive sense RNAvirus in the family Flaviviridae. HCV has a high rate of replication with approximately one trillion particles produced each day in an infected individual. Due to lack of proofreading by the HCV RNA polymerase, the HCV has an exceptionally high mutation rate, a factor that may help it elude the host's immune response. Hepatitis C virus is classified into six genotypes(1-6) with several subtypes within each genotype. The preponderance and distribution of HCV genotypes varies globally. Genotype is clinically important in determining potential response to interferon-based therapy and the required duration of such therapy. Genotypes 1 and 4 are less responsive to interferon-based treatment than are the other genotypes (2, 3, 5 and 6).

Product Categories/Family for HCV recombinant protein

Viral Antigens; HEPATITIS C VIRUS; Viral Antigens; Hepatitis C

NCBI and Uniprot Product Information

• NCBI GI #: 157781209
• NCBI GeneID: 11027168
• NCBI Accession #: YP_001469632.1
• NCBI GenBank Nucleotide #: NC_009825.1
• UniProt Accession #: O39929
• Molecular Weight: 327,599 Da
• NCBI Official Full Name: HCV polyprotein
• NCBI Official Symbol: HCV4_gp1
• NCBI Protein Information: HCV polyprotein
• UniProt Protein Name: Genome polyprotein
• UniProt Gene Name: p23
• UniProt Synonym Gene Names: NS4A; NS4B; NS5A
• UniProt Entry Name: POLG_HCVED

Uniprot Description

Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis) ().